Ixempra for IBC?
Meet the Experts
Jennifer Griggs, M.D., M.P.H. is a medical oncologist specializing in the treatment of breast cancer, dedicated to developing programs that improve the well-being of women treated for breast cancer.
Question from Hania: Has the new drug Ixempra shown any promise in the treatment of advanced Stage IV inflammatory breast cancer (triple positive) HER2-overexpressing, but insensitive to Herceptin, Tykerb, and Xeloda?
- Answer —Jennifer Griggs, M.D., M.P.H.:
Studies focusing specifically on the use of this class of drug called the epothilones have not been done, but there's no reason to think that the drug, Ixempra (chemical name: ixabepilone), would be any less effective in inflammatory breast cancer that has progressed on other chemotherapy agents. So certainly a trial of this drug would be warranted, given its promise in clinical trials.
On December 19, 2007, our Ask-the-Expert Online Conference was called Updates from San Antonio 2007. Jennifer Griggs, M.D., M.P.H. answered your questions and shared the newest research presented at this year's San Antonio Breast Cancer Symposium.
The materials presented in these conferences do not necessarily reflect the views of breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2008. All rights reserved.